ArticleNucleic acid therapeutics2016
Aptamer-Enabled Manipulation of the Hsp70 Chaperone System Suggests a Novel Strategy for Targeted Ubiquitination.
Article in Nucleic acid therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Degradation of proteins by PROTACs and other strategies.Acta pharmaceutica Sinica. B · 2020Review
- RNA aptamers targeted for human αA-crystallin do not bind αB-crystallin, and spare the α-crystallin domain.Biochemical and biophysical research communications · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The Hsp70 chaperone system plays an important role in protein quality control by assisting in the folding and clearance of misfolded proteins. However, the mechanism by which it chooses between folding and degradation pathways is not fully understood. In this study, we used an RNA aptamer for Hsp70 to perturb the function of Hsp70 in cell-free systems. We found that the aptamer inhibited both Hsp70-mediated folding and Hsp70-CHIP-mediated ubiquitination/degradation of a misfolded protein substrate. Based on these results, we explored a novel strategy for targeted protein ubiquitination, using an engineered bifunctional aptamer to tether a protein substrate to Hsp70. We demonstrated that increased Hsp70-CHIP-mediated ubiquitination of the tethered protein substrate can be specifically induced by this bifunctional aptamer. This strategy may be useful in selective degradation of disease-causing proteins for therapeutic purposes. In addition, these studies provide insight into the mechanism of Hsp70-mediated protein triage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.